KalVista's Genetic Disease Treatment Triumphs in Late-Stage Study

DelSiTech Ltd., a pharmaceutical development and supply company, and Tolmar International Ltd., a fully integrated pharmaceutical company, have strengthened their partnership by signing a global licensing and development agreement following Tolmar's investment in January 2024.

Under the terms of the agreement, Tolmar will obtain a worldwide license to use DelSiTech's silica-based drug delivery technology platform for the development and commercialization of two long-acting injectable pharmaceutical products. In addition, the two companies will work together to explore development opportunities through silica matrix-based drug delivery in a wide range of medical areas, including urology, reproductive health and pediatric endocrinology.

Under the terms of the license agreement, DelSiTech is entitled to receive upfront fees, development and trademark fees, and royalties on net sales of licensed products. The amount was not disclosed.

"We are excited to expand our partnership with Tolmar, which demonstrates the strength of our silica-based drug delivery technology platform," said Lasse Leino, CEO of DelSiTech. "By combining and combining our experience with new drug delivery technologies, we have the capacity and capability to develop new products to benefit patients who want to improve their treatments." this license agreement is a step forward following Tolma's investment earlier this year."

"Our collaboration with DelSiTech is an opportunity to strengthen Tolmar's position as a leader in long injection and bring another exciting technology to Tolmar as we expand our portfolio to benefit patients. "We can provide." Anil D'Souza, President and CEO of Tolmar, said:

Silica matrices are an advanced technology platform for the basic and purposeful management of injections, implant formulations, and eye drops. The effective technology in a silica matrix (SiO2) integrated with molecules or therapeutic agents of interest using the so-called sol-gel technique. The resulting silica matrix is ​​non-porous, biocompatible, and designed to biodegrade by dissolution of the matrix at the desired rate. It can release active substances over periods of up to several months, up to or with age